Myeloproliferative Neoplasms section

Myeloproliferative Neoplasms News & Features

Recommended Therapies for Polycythemia Vera Underused

Recommended Therapies for Polycythemia Vera Underused

Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients.

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.

Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype

Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype

In a review of data from DANHES study, researchers determined the hazard ratio for developing myeloproliferative neoplasm — any or by subtype — among smokers, occasional smokers, and ex-smokers, compared with never smokers.

Case Study: Myelofibrosis Diagnosis and Early Intervention

Case Study: Myelofibrosis Diagnosis and Early Intervention

In this Case Study, Ms Lyle discusses diagnosis and early management of myelofibrosis in a 72-year-old male patient.

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status

Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status

Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs